Search

Displaying results 1141 - 1150 of 7604 in total
  1. Drug

    Azacitidine

    go.drugbank.com/drugs/DB00928
    ApprovedInvestigational

    myeloid leukemia (AML), two types of cancer characterized by the presence of aberrant DNA methylation. … [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335]

  2. Drug

    Pectin

    go.drugbank.com/drugs/DB11158
    ApprovedInvestigationalVet approved

    This status allows pectin to be used with no limitations.[L1960]

    Mixtures: NEO ASTA, NEO DIAFORM
  3. Drug

    Nelarabine

    go.drugbank.com/drugs/DB01280
    ApprovedInvestigational

    [A258719] Nelarabine was first granted accelerated approval by the FDA on October 28, 2005, and was manufactured under the trademark name ARRANON by GlaxoSmithKline. … [A2332] Due to the rarity of these T-cell malignancies, nelarabine was first granted orphan drug status and a fast-track designation by the FDA to address the unmet therapeutic needs of these cancers.

  4. Drug

    Palonosetron

    go.drugbank.com/drugs/DB00377
    ApprovedInvestigational

    HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by … As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Neostigmine

    go.drugbank.com/drugs/DB01400
    ApprovedInvestigationalVet approved

    Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. … A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine.

    Synonyms: 3-Trimethylammoniumphenyl N,N-dimethylcarbamate
  6. Drug

    Pimecrolimus

    go.drugbank.com/drugs/DB00337
    ApprovedInvestigational

    Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.

    Categories: Analgesics, Non-Narcotic
  7. Drug

    Protein C

    go.drugbank.com/drugs/DB11312
    ApprovedInvestigational

    It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). … APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot

    Mixtures: Beriplex P/n 500, Beriplex P/n 1000
  8. Drug

    Elagolix

    go.drugbank.com/drugs/DB11979
    ApprovedInvestigational

    Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. … unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain.

  9. Drug

    Autologous cultured chondrocytes

    go.drugbank.com/drugs/DB10997
    ApprovedInvestigational

    The surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis. … Autologous cultured chrondrocytes are used as autologous cell therapy to repair articular cartilage injuries in the knee (femoral condyle) due to acute or repetitive trauma.

  10. Drug

    Sotalol

    go.drugbank.com/drugs/DB00489
    ApprovedInvestigational

    [A178579] Sotalol was first approved as an oral tablet on 30 October 1992.

    Categories: Beta Blocking Agents, Non-Selective, Beta Blocking Agents, Non-Selective, and ThiazidesProducts: Co Sotalol